Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.…
Nordic outperformance widens, US biotech retreats sharply
Modus Therapeutics Holding (STO: MODTX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.1345 SEK on 20 November 2026, down 65.5% over 52 weeks. Its 52-week range is 0.1300 SEK to 0.5960 SEK: the price is 77.4% below the high and 3.5% above the low.
Its market capitalisation is 22.74M SEK.
Modus Therapeutics Holding reports return on equity of -204.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 12.49M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.